Voluntary Quarterly Statement as of Sep 30, 2026

Novogenia AG

formerly Darwin AG

At a Glance

Novogenia Group	in EUR thousands	in EUR thousands
Balance Sheet Key Figures*	**30.09.2026**	**31.12.2025**
Total Assets	107,386	119,382
Equity	90,817	100,091
Equity Ratio (%)	84.6	83.8
Trade Receivables	8,525	4,333
Trade Payables	6,480	3,232
Cash and Cash Equivalents	5,213	12,529
Banks Liabilities	5,360	6,152
Income Statement Key Figures*	**9M 2026**	**9M 2025**
Group Revenue	43,025	41,365
Gross Profit	13,818	17,360
Earnings before Interest, Taxes, Depreciation and Amortisation (EBITDA)	-5,578	-3,821
Operating Result (EBIT)	-7,290	-5,835
Financial Result	4,884	10,469
Group Earnings before Taxes (EBT)	-2,406	4,634
Group Earnings after Taxes (EAT)	-2,535	3,897
Group Earnings per Share in EUR	-0.21	0.32

*unaudited, not reviewed

Letter from the Management Board

Dear Shareholders,

In the third quarter of 2026, revenue at the Novogenia Group accelerated significantly. Quarterly revenue rose to EUR 17.4 million, 27% above the prior-year quarter (EUR 13.7 million). The main driver was the recovery of the pharmaceutical and medical device trading business expected for the second half of the year, which was achieved by expanding the range of services.

However, revenue growth has not yet translated into an improvement in the operating result. Due to the higher share of lower-margin trading revenue, gross profit in the third quarter amounted to EUR 4.4 million (prior-year quarter: EUR 6.4 million). It should be noted that the prior-year figure included extraordinary other operating income of EUR 1.3 million. Personnel expenses and other operating expenses, on the other hand, were again below the prior-year level in the third quarter. EBITDA for the quarter amounted to EUR -2.0 million and EBIT to EUR -2.6 million. A positive financial result of EUR 2.2 million, including income from equity investments of EUR 2.0 million, limited the loss after taxes to EUR 0.4 million.

In the third quarter, we also set the course for our further development. Our strategic focus remains the international expansion of our core business of genetic analyses and the personalised health products based on genetic insights. Together with our US partner 10X Health, we launched the expanded MGT plus methylation testin the United States in August. In doing so, we are strategically advancing our joint product pipeline and unlocking additional potential in a key growth market for Novogenia.

We have also made significant progress in advancing our collaboration with M42 and preparing for the deployment of our technologies in the Middle East. After the end of the reporting period, we announced that we will be part of a planned clinical study as Part of the 10XREVIV Initiative in Abu Dhabi, in which M42, among others, is involved as a healthcare partner. The study is intended to examine the benefits of personalised dietary supplements for people receiving GLP-1 therapy, whose diet often deteriorates during weight loss. Novogenia will conduct the DNA analyses, evaluate the results, as well as develop and produce the personalised dietary supplements. The halal certification of our production required for this has been

completed. In this way, we are bringing our core competencies into a new medical application concept and deepening our international partnerships.

At the same time, we are laying the foundation for long-term growth at our site in Hallwang near Salzburg, where the official groundbreaking for our new company building took place in July and construction is progressing well. The planned laboratory, production and research capacities on the innovative Novogenia Campus are intended to support the further expansion of our core business. With the change of name to Novogenia AG, also completed in July, the Group now operates under the brand of its operating core business, strengthening the Group's common brand presence.

The significant increase in revenue, the further reduced cost base and the progress in our international partnerships form a solid basis for Novogenia's further development. Our goal remains to translate growth into a sustainable improvement in earnings power. With this focus, we look ahead to the 2027 financial year with confidence.

Munich, 20 November 2026

Yours sincerely

Novogenia AG





Dr. Daniel Wallerstorfer

Founder and CEO

Felix Bausch

CIO

Consolidated Income Statement

		9M 2026	9M 2025
		EUR	EUR
1.	Revenue	43,025,215.03	41,365,109.26
2.	Increase or decrease in inventories of finished goods and work in progress	306,167.29	45,744.86
	Total output	**43,331,382.32**	**41,410,854.12**
3.	Other operating income	207,978.19	4,786,374.44
4.	Cost of materials:		
	a) Cost of raw materials, consumables and supplies and of purchased merchandise	-28,530,724.95	-28,035,718.29
	b) Cost of purchased services	-1,190,171.04	-801,791.47
5.	Personnel expenses:		
	a) Wages and salaries	-8,610,384.68	-9,294,346.87
	b) Social security, pension and other employee benefit expenses	-1,946,689.67	-2,048,468.19
6.	Depreciation and amortisation		
	a) of intangible non-current assets and property, plant and equipment	-1,711,106.61	-2,013,639.02
7.	Other operating expenses	-8,839,842.11	-9,837,899.48
	Operating result	**-7,289,558.55**	**-5,834,634.76**
8.	Income from equity investments	2,048,024.90	0.00
9.	Income from other securities held as current assets	597,013.51	4,285,556.53
10.	Other interest and similar income	609,416.93	920,387.67
11.	Income from disposals of and reversals of impairment on financial assets and securities held	2,257,943.81	6,016,405.37
12.	Write-downs of financial assets and securities held as current assets	-259,312.22	-342,880.81
13.	Interest and similar expenses	-369,036.00	-410,515.34
14.	**Financial result**	**4,884,050.93**	**10,468,953.42**
15.	**Earnings before taxes**	**-2,405,507.62**	**4,634,318.66**
16.	Income taxes	-129,080.66	-737,637.52
17.	**Earnings after taxes**	**-2,534,588.28**	**3,896,681.14**
18.	Other taxes	-2,942.48	-2,954.96
19.	Non-controlling interests	298,687.26	53,678.46
20.	**Consolidated net income**	**-2,238,843.50**	**3,947,404.64**

Notes to the Consolidated Income Statement

After nine months, Group revenue amounted to EUR 43.0 million, exceeding the prior-year figure of EUR 41.4 million. At EUR 0.2 million, other operating income was significantly below the prior-year figure of EUR 4.8 million. The prior-year figure included income of EUR 3.8 million from the imputed reversal of provisions, which no longer arises in the current financial year. Adjusted for this extraordinary income, the operating result (EBIT) improved by EUR 2.3 million in the first nine months of 2026 and amounted to EUR -7.3 million compared with EUR -5.8 million in the prior year.

Personnel expenses decreased by 7% to EUR 10.6 million and other operating expenses by 10% to EUR 8.8 million. This mainly reflects lower expenses for the development of software systems and the cost-cutting measures that have been initiated.

The financial result amounted to EUR 4.9 million (prior year: EUR 10.5 million). For the first time, it includes income from equity investments of EUR 2.0 million resulting from a partial sale of the investment in GenePlanet d.o.o., Ljubljana, Slovenia. At EUR 2.9 million, income from securities and from the disposal and write-up of financial assets and securities was significantly below the prior-year figure of EUR 10.3 million. This is also due to the smaller securities portfolio.

Consolidated Balance Sheet

ASSETS	30.09.2026	31.12.2025
A. Fixed assets	**48,638,937.45**	**43,544,419.05**
I. Intangible assets	6,820,120.75	7,269,717.69
1. Concessions, industrial property rights and similar rights and assets acquired for consideration, and licences in such rights and assets	2,007,771.26	1,987,509.70
2. Goodwill	4,812,349.49	5,282,207.99
II. Property, plant and equipment	16,995,209.68	9,974,693.34
1. Buildings	758,329.22	785,885.75
2. Technical equipment and machinery	3,206,983.25	2,818,778.36
3. Other equipment, operating and office equipment	2,243,212.31	1,716,895.42
4. Payments on account and assets under construction	10,786,684.90	4,653,133.81
III. Financial assets	24,823,607.02	26,300,008.02
1. Equity investments	1,823,605.02	1,300,005.02
2. Loans to other long-term investees	1.00	2.00
3. Other loans	1.00	1.00
4. Securities held as non-current assets	23,000,000.00	25,000,000.00
B. Current assets	**56,123,810.73**	**74,657,333.62**
I. Inventories	10,561,780.40	10,626,685.90
1. Raw materials, consumables and supplies	7,075,226.53	7,518,689.78
2. Finished goods and merchandise	3,132,908.37	1,819,729.67
3. Payments on account for inventories	0.00	251,445.94
4. Work in progress	353,645.50	1,036,820.51
II. Receivables and other assets	12,220,377.41	11,014,816.81
1. Trade receivables	8,525,408.97	4,333,365.08
2. Other assets	3,694,968.44	3,480,905.19
3. Receivables from entities in which an equity interest is held	0.00	3,200,546.54
III. Securities held as current assets	28,128,572.06	40,486,532.58
IV. Cash on hand and bank balances	5,213,080.86	12,529,298.33
C. Prepaid expenses	**2,623,480.74**	**1,179,774.90**
D. Deferred tax assets	**139.53**	**139.53**
Total assets	**107,386,368.45**	**119,381,667.10**

EQUITY AND LIABILITIES	30.09.2026	31.12.2025
A. Equity	**90,816,965.24**	**100,090,934.54**
I. Subscribed capital	12,000,000.00	12,000,000.00
II. Capital reserve	8,700,001.00	8,700,001.00
III. Retained earnings	28,025,588.37	28,025,588.37
IV. Difference from currency translation	-8,825.35	-7,714.69
V. Consolidated retained earnings	42,471,458.61	51,445,731.65
VI. Non-controlling interests	-371,257.39	-72,671.79
B. Provisions	**2,217,251.05**	**3,895,819.40**
I. Tax provisions	81,249.46	981,426.09
II. Other provisions	2,136,001.59	2,914,393.31
C. Liabilities	**13,285,686.07**	**14,784,030.47**
1. Liabilities to banks	5,359,764.81	6,151,878.88
2. Payments received on account of orders	0.00	11,353.22
3. Trade payables	6,480,493.62	3,231,811.45
4. Other liabilities	1,445,427.64	1,193,119.42
5. Liabilities to entities in which an equity interest is held	0.00	4,195,867.50
D. Deferred income	**1,062,575.98**	**606,992.57**
E. Deferred tax liabilities	**3,890.11**	**3,890.11**
Total equity and liabilities	**107,386,368.45**	**119,381,667.10**

©Novogenia AG 2026

Notes to the Consolidated Balance Sheet

Advance payments and assets under construction increased to EUR 10.8 million (31 Dec 2025: EUR 4.7 million). The increase is mainly attributable to the construction of the new company building in Hallwang near Salzburg, which is scheduled for completion in early 2028. In addition, the operating building of MEDICOPHARM AG is recognised in the consolidated balance sheet.

As of 31 December 2025, liabilities to other long-term investees related to outstanding dividend payments to major shareholders. As of 30 September 2026, these had been settled in full (31 Dec 2025: EUR 4.2 million). The related loan receivables from other long-term investees had likewise been settled in full as of the reporting date (31 Dec 2025: EUR 3.2 million). Provisions decreased to EUR 2.2 million (31 Dec 2025: EUR 3.9 million). Tax provisions declined to EUR 0.1 million (31 Dec 2025: EUR 1.0 million) and other provisions to EUR 2.1 million (31 Dec 2025: EUR 2.9 million).

As of 30 September 2026, the Novogenia Group held current securities and cash and cash equivalents of EUR 33.3 million (31 Dec 2025: EUR 53.0 million) as well as non-current securities of EUR 23.0 million (31 Dec 2025: EUR 25.0 million). Equity amounted to EUR 90.8 million which, with total assets of EUR 107.4 million, corresponds to an equity ratio of 84.6% (31 Dec 2025: 83.8%).

©Novogenia AG 2026

Novogenia AG

Brienner Straße 7

80333 Munich

investor.relations@novogenia.com

www.novogenia.com